主页 > 医药科学 >
【medical-news】芳香酶抑制剂很可能有助于乳腺癌
Study identifies women with breast cancer most likely to benefit from aromatase inhibitor
While some breast cancer survivors could benefit from adding aromatase inhibitors to the standard five years of tamoxifen, a new study shows the additional therapy should be weighed carefully for each individual. Writing in the December 1, 2006 issue of CANCER (http://www.interscience.wiley.com/cancer-newsroom), a peer-reviewed journal of the American Cancer Society, the study's authors say potential improvement in cancer-free survival beyond 5 years with the added therapy may be less than 2 percent for most patients.
For decades, clinicians have given breast cancer patients tamoxifen, which has been shown to improve survival when given for five years. More recently, aromatase inhibitors, another class of estrogen modulating drugs, have been used to prevent estrogen formation. A large randomized study has shown that use of aromatase inhibitors after tamoxifen may further improve survival and is recommended for postmenopausal women. Led by Gary M. Freedman, M.D. of the Fox Chase Cancer Center in Philadelphia, researchers investigated which sub-groups of breast cancer patients treated with tamoxifen may benefit the most from this extended therapy with aromatase inhibitors.
The researchers found that in this study population of 471 women, the potential addition of an aromatase inhibitor would have provided only marginal benefits. Premenopausal women and patients with at least four positive lymph nodes would experience the greatest 10-year cancer-free survival benefits. Patients with none or fewer positive lymph nodes, advanced age, or other medical problems that would limit their life expectancy would not have the same benefit from 5 more years of therapy.
"Based upon our findings," the authors conclude, "women who are premenopausal at the time of initial therapy and patients who have 4 or more positive lymph nodes will have the greatest potential benefit from the addition of extended adjuvant anti-estrogen therapy." For patients over 60 years old, "the decision needs to be individualized based upon their initial nodal status and presence of comorbidities that would reduce their 5-year life expectancy." 认领了 芳香酶抑制剂很可能有助于乳腺癌患者的治疗
虽然一些乳腺癌生存者可能受益于将芳香酶抑制剂加入到标准的5年三苯氧胺治疗方案，但一项新的研究显示这项附加治疗应该个体化。该项研究发表于2006年11月1日出版的《癌症》杂志上。这项研究的作者认为采用这项附加的治疗对提高乳腺癌患者的5年生存率有潜在性作用，但受益者不到2％。
几十年来，临床医生对乳腺癌患者给予三苯氧胺治疗，当给予该药治疗5年可提高患者的生存期。最近，另一类调控雌激素的药物芳香酶抑制剂被用于组织雌激素。一项大的随机研究显示在三苯氧胺后使用芳香酶抑制剂可明显提高乳腺癌患者生存期，并推荐在绝经后的乳腺癌患者。由费城FOX CHASE癌症中心Gary M. Freedman博士领导的研究小组调查了哪些采用三苯氧胺治疗的乳腺癌患者最受益于这种附加的芳香酶抑制剂的治疗。
研究者调查了471名乳腺癌病人，研究发现另外使用芳香酶抑制剂近产生了边缘益处，绝经前和至少4个淋巴结阳性的乳腺癌病人可获得10年无瘤生存期，而无或较少淋巴结转移，老年和有其他影响寿命的疾病者则没有从5年多的治疗中受益。
作者推断：“根据他们的研究发现，开始治疗时处于绝经前和有4个或以上淋巴结转移的乳腺癌病人能够最大限度地从这项治疗中受益。”对于60 岁以上的病人，“治疗需要个体化，这取决于她们的开始的淋巴结情况和能减少其5年预期寿命的并存病。” [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-07-05 05:52
医学,生命科学网